Literature DB >> 25311333

Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention.

Sharon L Bober1, Christopher J Recklitis, Jennifer Bakan, Judy E Garber, Andrea F Patenaude.   

Abstract

INTRODUCTION: Women at high risk for ovarian cancer due to BRCA1 or BRCA2 mutation or family history are recommended to undergo risk-reducing salpingo-oophorectomy (RRSO) after age 35 or completion of childbearing. This potentially life-saving surgery leads to premature menopause, frequently resulting in distressing and unaddressed sexual dysfunction. AIM: To pilot a novel sexual health intervention for women with BRCA1/2 mutations who previously underwent RRSO a using a single-arm trial. Feasibility and primary outcomes including sexual dysfunction and psychological distress were assessed.
METHODS: This single-arm trial included a one-time, half-day educational session comprised of targeted sexual health education, body awareness and relaxation training, and mindfulness-based cognitive therapy strategies, followed by two sessions of tailored telephone counseling. Assessments were completed at baseline and 2 months postintervention. MAIN OUTCOME MEASURE: Study end points include feasibility and effectiveness as reported by the participant.
RESULTS: Thirty-seven women completed baseline and postintervention assessments. At baseline, participants had a mean age of 44.4 (standard deviation [SD] = 3.9) years and mean duration of 3.8 (SD = 2.7) years since RRSO. Overall sexual functioning (P = 0.018), as well as desire (P = 0.003), arousal (P = 0.003), satisfaction (P = 0.028), and pain (P = 0.018), improved significantly. There were significant reductions in somatization (P = 0.029) and anxiety scores (P < 0.001), and, overall, for the Global Severity Index (P < 0.001) of the Brief Symptom Inventory. Sexual self-efficacy and sexual knowledge also improved significantly from baseline to postintervention (both P < 0.001). Women were highly satisfied with the intervention content and reported utilizing new skills to manage sexual dysfunction.
CONCLUSIONS: This intervention integrates elements of cognitive behavioral therapy with sexual health education to address a much-neglected problem after RRSO. Results from this promising single-arm study provide preliminary data to move toward conducting a randomized, controlled trial.
© 2014 International Society for Sexual Medicine.

Entities:  

Keywords:  Quality of Life and Cancer; Risk-Reducing Salpingo-Oophorectomy and Sexual Dysfunction; Sexual Health and Cancer

Mesh:

Substances:

Year:  2014        PMID: 25311333      PMCID: PMC4304978          DOI: 10.1111/jsm.12713

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  31 in total

1.  The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function.

Authors:  R Rosen; C Brown; J Heiman; S Leiblum; C Meston; R Shabsigh; D Ferguson; R D'Agostino
Journal:  J Sex Marital Ther       Date:  2000 Apr-Jun

2.  Risk reduction works for BRCA mutation carriers--with heavy costs.

Authors:  Cori Vanchieri
Journal:  J Natl Cancer Inst       Date:  2005-07-20       Impact factor: 13.506

3.  The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores.

Authors:  Markus Wiegel; Cindy Meston; Raymond Rosen
Journal:  J Sex Marital Ther       Date:  2005 Jan-Feb

4.  Psychoeducational group increases vaginal dilation for younger women and reduces sexual fears for women of all ages with gynecological carcinoma treated with radiotherapy.

Authors:  J W Robinson; P D Faris; C B Scott
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-06-01       Impact factor: 7.038

5.  Cancer treatment-induced menopause: meaning for breast and gynecological cancer survivors.

Authors:  C S Davis; J E Zinkand; M I Fitch
Journal:  Can Oncol Nurs J       Date:  2000

6.  Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy.

Authors:  Mark Robson; Martee Hensley; Richard Barakat; Carol Brown; Dennis Chi; Elizabeth Poynor; Kenneth Offit
Journal:  Gynecol Oncol       Date:  2003-05       Impact factor: 5.482

7.  A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer.

Authors:  Carolyn Y Fang; Carol Cherry; Karthik Devarajan; Tianyu Li; John Malick; Mary B Daly
Journal:  Gynecol Oncol       Date:  2009-01-13       Impact factor: 5.482

8.  Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.

Authors:  Mary B Daly; Robert Pilarski; Jennifer E Axilbund; Saundra S Buys; Beth Crawford; Susan Friedman; Judy E Garber; Carolyn Horton; Virginia Kaklamani; Catherine Klein; Wendy Kohlmann; Allison Kurian; Jennifer Litton; Lisa Madlensky; P Kelly Marcom; Sofia D Merajver; Kenneth Offit; Tuya Pal; Boris Pasche; Gwen Reiser; Kristen Mahoney Shannon; Elizabeth Swisher; Nicoleta C Voian; Jeffrey N Weitzel; Alison Whelan; Georgia L Wiesner; Mary A Dwyer; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2014-09       Impact factor: 11.908

9.  Efficacy trial of an Internet-based intervention for cancer-related female sexual dysfunction.

Authors:  Leslie R Schover; Ying Yuan; Bryan M Fellman; Evan Odensky; Pamela E Lewis; Paul Martinetti
Journal:  J Natl Compr Canc Netw       Date:  2013-11       Impact factor: 11.908

10.  Lack of communication between healthcare professionals and women with ovarian cancer about sexual issues.

Authors:  M L Stead; J M Brown; L Fallowfield; P Selby
Journal:  Br J Cancer       Date:  2003-03-10       Impact factor: 7.640

View more
  17 in total

1.  Sexual health and rehabilitation after ovarian suppression treatment (SHARE-OS): a clinical intervention for young breast cancer survivors.

Authors:  Sharon L Bober; E Fine; C J Recklitis
Journal:  J Cancer Surviv       Date:  2019-09-03       Impact factor: 4.442

2.  Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models.

Authors:  Yusuke Kobayashi; Hiroyasu Kashima; Ren-Chin Wu; Jin-Gyoung Jung; Jen-Chun Kuan; Jinghua Gu; Jianhua Xuan; Lori Sokoll; Kala Visvanathan; Ie-Ming Shih; Tian-Li Wang
Journal:  Clin Cancer Res       Date:  2015-06-24       Impact factor: 12.531

Review 3.  How to ask and what to do: a guide for clinical inquiry and intervention regarding female sexual health after cancer.

Authors:  Sharon L Bober; Jennifer B Reese; Lisa Barbera; Andrea Bradford; Kristen M Carpenter; Shari Goldfarb; Jeanne Carter
Journal:  Curr Opin Support Palliat Care       Date:  2016-03       Impact factor: 2.302

Review 4.  Physical examination of the female cancer patient with sexual concerns: What oncologists and patients should expect from consultation with a specialist.

Authors:  Stacy Tessler Lindau; Emily M Abramsohn; Shirley R Baron; Judith Florendo; Hope K Haefner; Anuja Jhingran; Vanessa Kennedy; Mukta K Krane; David M Kushner; Jennifer McComb; Diane F Merritt; Julie E Park; Amy Siston; Margaret Straub; Lauren Streicher
Journal:  CA Cancer J Clin       Date:  2016-01-19       Impact factor: 508.702

Review 5.  Outcomes of support groups for carriers of BRCA 1/2 pathogenic variants and their relatives: a systematic review.

Authors:  Benedetta Bertonazzi; Daniela Turchetti; Lea Godino
Journal:  Eur J Hum Genet       Date:  2022-01-26       Impact factor: 4.246

6.  The effect of the EX-PLISSIT model-based psychosexual counseling on improving sexual function and sexual quality of life in gynecologic cancer survivors: a randomized controlled clinical trial.

Authors:  Zohreh Mohammadi; Raziyeh Maasoumi; Nafiseh Vosoughi; Tahereh Eftekhar; Mehdi Soleimani; Ali Montazeri
Journal:  Support Care Cancer       Date:  2022-08-23       Impact factor: 3.359

7.  Talking about women's sexual health after cancer: Why is it so hard to move the needle?

Authors:  Jennifer Barsky Reese; Sharon L Bober; Mary B Daly
Journal:  Cancer       Date:  2017-11-08       Impact factor: 6.860

8.  How does genetic testing influence anxiety, depression, and quality of life? A hereditary breast and ovarian cancer syndrome suspects trial.

Authors:  Francisca Fernanda Barbosa Oliveira; Paulo Goberlânio de Barros Silva; Rosane Oliveira de Sant'Ana; Clarissa Gondim Picanço de Albuquerque; Maria Júlia Barbosa Bezerra; Deysi Viviana Tenazoa Wong; Flávio da Silveira Bitencourt; Isabelle Joyce de Lima Silva-Fernandes; Marcos Venicio Alves Lima
Journal:  Support Care Cancer       Date:  2020-11-05       Impact factor: 3.603

9.  Improvement in sexual function after ovarian cancer: Effects of sexual therapy and rehabilitation after treatment for ovarian cancer.

Authors:  Sharon L Bober; Christopher J Recklitis; Alexis L Michaud; Alexi A Wright
Journal:  Cancer       Date:  2017-09-07       Impact factor: 6.860

Review 10.  Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.

Authors:  George U Eleje; Ahizechukwu C Eke; Ifeanyichukwu U Ezebialu; Joseph I Ikechebelu; Emmanuel O Ugwu; Onyinye O Okonkwo
Journal:  Cochrane Database Syst Rev       Date:  2018-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.